OBJECTIVES: The study objective was to evaluate the impact of preimplantation balloon valvuloplasty on procedural outcomes in high-risk or no-option @entity1 with @entity472 undergoing Edwards Lifesciences (Irvine, @entity2948 ) Sapien valve placement. Paravalvular @entity337 has been associated with long-term mortality after transcatheter aortic valve replacement. Whether omitting preimplant balloon valvuloplasty affects @entity337 after Edwards Sapien transcatheter aortic valve replacement is currently unknown. METHODS: We retrospectively analyzed the clinical outcome of 121 consecutive @entity1 undergoing transapical (N  =  50) or transfemoral (N  =  71) Edwards Sapien transcatheter aortic valve replacement. Routinely, no preimplant balloon valvuloplasty was performed in transapical procedure as opposed to uniform preimplant balloon valvuloplasty in transfemoral cases. The incidence and severity of total and @entity337 and 30-day clinical outcomes were compared between the 2 cohorts. RESULTS: The average @entity1 's age was 84.4  years, with a higher prevalence of smoking history (68% vs 42%, P  =  .005) and @entity1095 (38% vs 20%, P  =  .03) in the @entity1 undergoing transapical replacement. The preprocedural transthoracic echocardiographic and computed tomography findings were similar between the 2 cohorts. After transcatheter aortic valve replacement, the incidence of mild to moderate @entity337 (42% transfemoral vs 38% transapical), @entity337 (39% transfemoral vs 30% transapical), device success (88.7% transfemoral vs 94.0% transapical), and 30-day composite end points (9.9% transfemoral vs 14.0% transapical) were comparable in both groups. Multivariate regression analysis revealed male gender (odds ratio, 2.7; 95% confidence interval, 1.18-6.35; P  =  .02) but not preimplant balloon valvuloplasty as an independent predictor for mild or greater @entity337 . CONCLUSIONS: Compared with transapical transcatheter aortic valve replacement without preimplant balloon valvuloplasty, @entity886 resulted in a similar degree of prosthesis-related regurgitation, device success, and 30-day composite safety outcomes.

Device success and 30-day clinical outcome in XXXX undergoing preimplant valvuloplasty in transfemoral versus omitting valvuloplasty in transapical transcatheter aortic valve replacement.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1095 :: ('MESH:D016491', 'Disease') :: ['peripheral vascular disease'] @entity2948 :: ('9337', 'Gene') :: ['Calif'] @entity886 :: ('MESH:C563178', 'Disease') :: ['preimplant balloon valvuloplasty before transfemoral transcatheter aortic valve replacement'] @entity337 :: ('MESH:D001022', 'Disease') :: ['aortic regurgitation', 'total aortic regurgitation', 'paravalvular aortic regurgitation'] @entity472 :: ('MESH:D001024', 'Disease') :: ['aortic stenosis']
@entity1 :: (9606,Species) :: ['patients']
